- Home
- CTNM
as of 12-31-2025 1:17pm EST
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 416.1M | IPO Year: | 2024 |
| Target Price: | $20.00 | AVG Volume (30 days): | 260.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.35 - $15.25 | Next Earning Date: | 10-30-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered CTNM Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Contineum Therapeutics Inc. (CTNM)
CMO & Head of Development
Avg Cost/Share
$12.06
Shares
3,611
Total Value
$43,558.41
Owned After
0
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$12.23
Shares
4,170
Total Value
$51,009.11
Owned After
164,392
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Watkins Tim | CTNM | CMO & Head of Development | Dec 29, 2025 | Sell | $12.06 | 3,611 | $43,558.41 | 0 | |
| Lorrain Daniel S. | CTNM | Chief Scientific Officer | Dec 23, 2025 | Sell | $12.23 | 4,170 | $51,009.11 | 164,392 |
Compare CTNM vs Leading Stocks
See how CTNM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CTNM Contineum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.